Real-world evidence reveals differential endocrine and dermatologic safety profiles among GLP-1 receptor agonists.
Sexual function is missing from the adverse-effect map of GLP-1 receptor agonists in dermatology.
Abstract
Real-world data suggests varying endocrine and dermatologic safety across GLP-1RAs like exendin-4, liraglutide, and dulaglutide.